RecruitingPhase 3NCT06563895
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Sponsor: Eidos Therapeutics, a BridgeBio company
Falls Church, VA · Richmond, VA · +38 more sites